1. Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
   Jingsong He et al, 2020, Frontiers in Pharmacology CrossRef
2. Can Neutrophil‐to‐Lymphocyte Ratio, Monocyte‐to‐Lymphocyte Ratio, and Platelet‐to‐Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
   Serife Solmaz Medeni et al, 2018, Clinical Transplantation CrossRef
3. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma
   Yuan Jian et al, 2016, Medicine CrossRef
4. Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A retrospective study from a single center
   GUANGZHONG YANG et al, 2015, Experimental and Therapeutic Medicine CrossRef
5. Fokale Läsionen in der Ganzkörper-MRT beim multiplen Myelom
   S. C. Brandelik et al, 2018, Der Radiologe CrossRef
6. Reactive bone marrow plasmacytosis: A common denominator with diverse etiology
   Vijay Kumar et al, 2022, Hamdan Medical Journal CrossRef
7. MMSA-1 expression pattern in multiple myeloma and its clinical significance
   Shan Meng et al, 2016, Clinical and Experimental Medicine CrossRef
8. Treatment of pediatric plasma cell myeloma type post‐transplant lymphoproliferative disorder with modern risk‐directed therapy
   Rebecca Epperly et al, 2018, Pediatric Blood & Cancer CrossRef
9. Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma
   Jihye Ha et al, 2022, Scientific Reports CrossRef
10. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
    Wen Gao et al, 2020, Cancer Medicine CrossRef
11. Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
    Yue Zhang et al, 2019, BioMed Research International CrossRef
12. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
    Sarah Goldman‐Mazur et al, 2020, American Journal of Hematology CrossRef
13. Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway
    Hongwei Wu et al, 2016, Oncology Letters CrossRef
14. Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
    GuoQing Wei et al, 2017, Experimental Hematology & Oncology CrossRef
15. Prognostic Value of 1q21 Gain in Multiple Myeloma
    Dangui Chen et al, 2019, Clinical Lymphoma Myeloma and Leukemia CrossRef
16. Correlation between conventional karyotype, interphase fish and immunophenotype in risk stratification of newly diagnosed plasma cell myeloma: An observational study
    Paresh Singhal et al, 2023, Medical Journal Armed Forces India CrossRef
17. The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients
    Ameni Jerbi et al, 2023, Annals of Hematology CrossRef